An interesting D-lemma: what is all the excitement about vitamin D?

Conradie M, MBChB, MMed, FCP(SA), CertEndo&Metab(SA), Specialist Physician
Ascott-Evans B, MBChB, FCP(SA), Specialist Physician
Division of Endocrinology, Department of Medicine, University of Stellenbosch
Correspondence to: Marli Conradie, e-mail: marliconradie@sun.ac.za
Keywords: vitamin D, skeletal health, disease

Abstract
There has been a dramatic interest in the importance of vitamin D, “the sunshine vitamin”, in the past few years with regard to its impact on various aspects of health and disease. Research into well-known skeletal effects, as well as extraskletal effects, has been overwhelming. At times it has been difficult to make informed clinical decisions regarding replacement, if needed at all. This article aims to provide the physician with a summary of the most important clinical effects of vitamin D, as well as give guidelines on testing for possible deficiency and consideration of replacement thereof.

Introduction
Extensive research over the past decade has led to major advances in our understanding of the importance of vitamin D in health and disease. A PubMed search, using the term “vitamin D”, limited to English articles that have been published in the past five years, revealed over 10 000 results. This renewed interest may be attributed to large studies that confirm the high level of nutritional vitamin D deficiency worldwide, to observational studies and metaanalyses that show a strong association between vitamin D deficiency and various chronic diseases, as well as to new insights that have emerged regarding the autocrine, paracrine and nonhormonal functions of activated vitamin D in humans. The above information explosion poses a challenge for clinicians. This article aims to provide a brief review of the issues that relate to vitamin D deficiency in the South African context.

Overview of vitamin D metabolism
Vitamin D exists in two forms: D2 (ergocalciferol) and D3 (cholecalciferol). There are also numerous circulating metabolites in humans. Vitamin D3 is produced in the skin under the influence of ultraviolet light (80%), or can be obtained from the diet (fatty fish and egg yolks). Vitamin D2 is found in some plant sources and manufactured commercially by the irradiation of ergosterol produced by yeast. Supplementation can either be with vitamin D2 or D3. Both forms can be stored in adipose tissue or can undergo hydroxylation in the liver, whereby 25-hydroxyvitamin D 25 (OH) vitamin D (calcidiol) [25(OH)D] is produced. This form is converted in the kidney (via 1α hydroxylase) to 1,25(OH)2 vitamin D (calcitriol), the biologically active form of vitamin D.

The vitamin D receptor is a nuclear receptor of the thyroid hormone receptor superfamily. All tissues in the body express the vitamin D receptor and can respond to circulating calcitriol. Furthermore, it has been shown that many tissues, including the colon, pancreas, breast, prostate, immune system, macrophages, vascular endothelium, epidermis and placenta, possess the enzymes to produce 1,25(OH)2 vitamin D locally. This may explain why vitamin D appears to play an essential role in overall health.

Measurement of vitamin D status
The 25(OH)D level best reflects the body’s overall vitamin D status, as it is more stable than 1,25(OH)2 vitamin D, with a much longer half-life. The level reflects both dietary intake and sunlight exposure, as well as converted vitamin D. The level is stored in fat. However, 25(OH)D assays are not standardised at the present time. It is essential for the clinician to use method-specific reference ranges and carry out patient follow-up at the same laboratory.

Vitamin D deficiency
Currently, normal vitamin D status is defined as a 25(OH)D serum level of > 30 ng/ml (> 75 nmol/l). The
World Health Organization previously defined (true) deficiency as levels below 10 ng/ml (< 25 nmol/l). However, the lower limit of normal still remains a topic of much debate. More recently, the term “vitamin D insufficiency” has been introduced to describe suboptimal levels (typically between 10 and 30 ng/ml (25-75 nmol/l) of 25(OH)D associated with adverse outcomes2,3 (Table I).

Various reviews have described functional measures that are used to evaluate the adequacy of vitamin D levels.1,2

| Level                        | Interpretation  |
|------------------------------|-----------------|
| Normal status                | > 30 ng/ml (75 nmol/l) |
| Vitamin D insufficiency      | 10-30 ng/ml     |
| Vitamin D deficiency         | < 10 ng/ml      |
|                              | < 25 nmol/l     |

These include the 25(OH)D level at which there is maximal intestinal calcium reabsorption and no further increase in 1,25(OH)2 vitamin D levels with replacement and the level which maximally suppresses parathyroid hormone (PTH) secretion. The measurement of 25(OH)D is the most suitable indicator of vitamin D status.2 In a South African study, it was found that PTH levels rose significantly once the 25(OH)D level dropped below 10 mg/ml (25 nmol/l), but that more than half these patients still had calcium levels in the normal range.4

There has been a substantial increase in the prevalence of vitamin D deficiency in the past few years, as demonstrated by population-based studies like the National Health and Nutrition Examination Survey (NHANES) in the USA, where 25-30% of the population had frank vitamin D deficiency.1 This was noted across all age groups. Males and females were equally affected and non-Caucasoid populations were at the highest risk. Associated factors with this decline in vitamin D levels include a decrease in the intake of milk products, more liberal sunscreen use and sun avoidance, race, season, as well as the global increase in the prevalence of obesity.1

Diseases and outcomes associated with vitamin D deficiency

The classic outcomes of vitamin D deficiency are nutritional rickets (affecting growing bone) and osteomalacia (in adults). However, recently, it has become apparent that there are numerous other skeletal, as well as interesting nonskeletal benefits in having adequate vitamin D levels.2

These will be discussed here.
which in turn regulates insulin secretion. In addition, it also has a direct effect on pancreatic B cells, as well as effects on inflammatory mediators.\textsuperscript{17,20} It has been demonstrated that obesity (a known risk factor for type 2 diabetes mellitus) is associated with low vitamin D levels. However, interventional studies showing benefit are still lacking at this stage.\textsuperscript{21}

**Skin diseases**

In a country renowned for its sunshine, the beneficial as well as harmful effects of ultraviolet (UV) radiation are apparent. Protection against UV radiation is advocated in order to reduce the risk of cancer, although this can lead to a marked reduction in vitamin D levels.\textsuperscript{22} Further work is necessary to define the adequate amount of sun exposure to obtain optimal vitamin D levels, especially in the South African climate. However, it is imperative that a balanced view is maintained of the positive (vitamin D) and negative (skin cancer risk) effects of UV radiation. Monitoring and supplementation with vitamin D is essential in patients at risk of developing vitamin D deficiency (the elderly and people who cover up for religious reasons).\textsuperscript{23} Interestingly, topical vitamin D derivatives are also used in the treatment of psoriasis.\textsuperscript{24}

**Infectious diseases and immunity**

The relationship between vitamin D and the immune system was recognised a number of years ago with the demonstration of increased circulating levels of 1,25(OH)\textsubscript{2}D and hypercalcaemia and hypercalcaemia in sarcoidosis. This is because of the increased local activity of 1-α-hydroxylase which is found in activated macrophages.\textsuperscript{25} It is now clear that dysregulation of vitamin D homeostasis is not only present in sarcoidosis, but also in other forms of granulomatous disease and cancer.

Today, it is recognised that vitamin D plays a more active role in the immune system.\textsuperscript{26} It is involved in the differentiation of monocytes to mature phagocytic macrophages, and more recently, has been demonstrated to affect the phagocytic process by stimulating the expression of the antibacterial protein, cathelicidin.\textsuperscript{27} Regulation of this protein has also been described in other cell types, notably keratinocytes, lung epithelial cells, myeloid cells and placental trophoblasts.\textsuperscript{28}

Low-serum vitamin D levels are associated with a higher risk of active tuberculosis.\textsuperscript{29} Considerable work has been carried out into the role of vitamin D supplementation in the management of tuberculosis, but to date the results have been conflicting. It has not been demonstrated to have a convincing effect on sputum conversion or mortality.\textsuperscript{29,30}

Vitamin D deficiency is also very prevalent in human immunodeficiency virus (HIV)-infected individuals.\textsuperscript{31} It has been shown that there is inadequate 1-α-hydroxylation and decreased levels of 1,25(OH)\textsubscript{2}D, possibly because of increased levels of TNF-α. This may contribute to the impaired immune response and the pathogenesis of HIV-related immunodeficiency.\textsuperscript{32} Moreover, non-nucleoside reverse transcriptase inhibitors, notably efavirenz, have been implicated in lowering vitamin D levels.\textsuperscript{33}

Observational epidemiological studies have shown an increased risk of other viral infections (influenza and respiratory tract infections) associated with vitamin D deficiency.\textsuperscript{34}

**Cancer risk**

The active form of vitamin D, calcitriol, has been shown to slow tumour growth in animal models.\textsuperscript{35} Various mechanisms are postulated, including inhibition of cell proliferation and enhanced apoptosis, inhibiting angiogenesis and suppressing inflammation and metastases. Observational studies also show vitamin D deficiency to be associated with an increased risk of developing cancer, notably breast, colon and prostate cancer.\textsuperscript{36} As a result of encouraging preclinical data, vitamin D has been studied extensively as an anticancer drug, but the results have been disappointing to date.\textsuperscript{37}

**Rheumatologic diseases**

Vitamin D is thought to protect against rheumatic diseases [rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE)] through its effects on immune tolerance.\textsuperscript{27} A lower vitamin D level is associated with more severe and active disease in RA.\textsuperscript{38} The seasonal variation in vitamin D levels (lower in winter and higher in summer) negatively correlates with disease activity both in RA and SLE.\textsuperscript{22,24,39}

**Other diseases**

Vitamin D deficiency has also been associated with various other diseases, including multiple sclerosis,\textsuperscript{40} asthma,\textsuperscript{41} schizophrenia,\textsuperscript{42} gastrointestinal and liver disease\textsuperscript{43} and dementia.\textsuperscript{44}

**So how much is enough?**

There is little consensus in the literature regarding the exact dosing, as well as optimal route of administration that is most beneficial. It is recommended that vitamin D supplementation should not be offered routinely, but that individuals at risk of deficiency (Table II) should be screened. In cases of severe deficiency, large doses (e.g. a once-weekly dose of 50 000 IU of D2 or D3 for six weeks, followed by a maintenance dose of 400-1000 IU per day) may be required, and this may even
increase in obese patients, patients with malabsorption syndromes and patients on medication that affects vitamin D metabolism. 45

Table II: Individuals at risk of vitamin D deficiency46

| Malabsorption syndromes | Cystic fibrosis | Inflammatory bowel disease | Bariatric surgery | Radiation enteritis | Coeliac disease | Chronic pancreatitis |
|-------------------------|-----------------|---------------------------|------------------|-------------------|---------------|-------------------|

**Hyperparathyroidism**

**Medications**

- Anti-seizure
- Glucocorticoids
- Acquired immune deficiency syndrome
- Antifungals, e.g. ketoconazole
- Cholestyramine

Pregnant and lactating women

Older adults with a history of falls and nontraumatic fracture

Obese adults and children (body mass index > 30 kg/m2)

**Conclusion**

Vitamin D deficiency has been linked to a number of diseases. However, until now, intervention studies have been fairly disappointing, other than proving that vitamin D is beneficial in skeletal disease. There is still some debate regarding the recommended daily allowance and the required optimal dose for standard supplementation, but meeting daily requirements in adults of 800-1000 IU should be adequate in most people who are at risk of vitamin D deficiency.

**References**

1. Adams JS, Hewison M. Update in Vitamin D. J Clin Endocrinol Metab. 2010;95(7):2461-2478.
2. Thacher TD, Clarke BL. Vitamin D Insufficiency. Mayo Clin Proc. 2011;86(1):50-60.
3. Holick MF. The vitamin D deficiency pandemic and consequences for nonskeletal health: mechanisms of action. Mol Aspects Med. 2008;29(6):361-369.
4. Bikle D. Nonclassic actions of vitamin D. J Clin Endocrinol Metab. 2009;94(1):26-34.
5. Rosen C. Vitamin D Insufficiency. N Engl J Med. 2011;364:248-254.
6. Hauburger D, Hoffmann M, Eramus RT, Piloy T. Relationship between vitamin D, calcium and parathyroid hormone in Cape Town. J Clin Pathol. 2009;62(6):567-569.
7. Averell A, Gillespie WJ, Gillespie LD, O’Connell D. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and postmenopausal osteoporosis. [Cochrane Review]. In: The Cochrane Library, Issue 2, 2009. Oxford: Update Software.
8. Bischoff-Ferrari HA. Dawson-Hughes B, Staehelin HB, et al. Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials. BMJ. 2009;339:b3392.
9. Houston DK, Toozie JA, Davis CC, et al. Serum 25-hydroxyvitamin D and physical function in older adults: the Cardiovascular Health Study Age-Related Changes Study. J Am Geriatr Soc. 2011;59(10):1793-1801.
10. Anweltler C, Montoro-Osado M, Schott AM, et al. Fall prevention and vitamin D in the elderly: an overview of the key rate of the non-bone effects. J Neuroeng Rehabil. 2010;7:52.
11. Bischoff-Ferrari HA. Vitamin D and fracture prevention. Endocrinol Metab Clin North Am. 2010;39(2):347-353.
12. Nadal MA, Szewczak MM, Wilham MD. Vitamin D and cardiovascular prevention. Cardiovasc Ther. 2010;28(4):e1-e12.
13. Vaidya A, Forhan JP. Vitamin D and hypertension: current evidence and future directions. Hypertension. 2010;56(6):774-779.
14. Pilz S, Tomaisch A, Drechsler C, et al. Vitamin D supplementation: a promising approach for the prevention and treatment of strokes. Curr Drug Targets. 2011;12(1):88-94.
15. Vacek JL, Varga SR, Good M, et al. Vitamin D deficiency and supplementation and relation to cardiovascular health. Am J Cardiol. 2012;109(9):539-563.
16. Hyypainen E, Vitamin D and increasing incidence of type 1 diabetes evidence for an association? Diabetes Obes Metab. 2010;12(9):737-743.
17. Alfonso B, Liao E, Buxta A, Paretyk L. Vitamin D in diabetes mellitus: a new field of knowledge poised for D-velopment. Diabetes Metab Res Rev. 2009;25(3):417-419.
18. Pittas AG, Lau J, Hu FB, Dawson-Hughes B. The role of vitamin D and calcium in type 2 diabetes: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2007;92(6):2017-2029.
19. Boucher BJ. Vitamin D Insufficiency and diabetes risks. Curr Drug Targets. 2012;13(1):61-87.
20. Palomer X, Gonzalez-Clemente JM, Blanco-Vaca F, Mauricio D. Role of vitamin D in the pathogenesis of type 2 diabetes mellitus. Diabetes Obes Metab. 2008;10(3):185-197.
21. Mitli J, Murrar MD, Pittas AG. Vitamin D and type 2 diabetes: a systematic review. Eur J Clin Nutr. 2011;65(9):1005-1015.
22. Holick MF, Matsuzaki Y, Wortsman J. Regular use of sunscreen on vitamin D levels. Arch Dermatol. 1995;131(11):1337-1339.
23. Reichrath J. Skin cancer prevention and UV-protection: how to avoid vitamin D deficiency? J Dermatol. 2009;26 Suppl 5:34-60.
24. Tanghetti E. The role of topical vitamin D modulators in psoriasis therapy. J Drugs Dermatol. 2009;8(9 Suppl):14-58.
25. Adams JS, Sharma OP, Gacad MA, Singer FR. Metabolism of 25-hydroxyvitamin D3 by cultured pulmonary alveolar macrophages in sarcoidosis. J Clin Invest. 1983;72(5):1556-1600.
26. Hewison M, Vitamin D and the immune system: new perspectives on an old theme. Endocrinol Metab Clin North Am. 2010;39(2):365-379.
27. Kemen DL, Tangpricha V. Vitamin D and molecular actions on the immune system: modulation of innate and autoimmune. J Mol Med. 2010;88(6):411-450.
28. Nhoaham KE, Clarke A. Low serum vitamin D levels and tuberculosis: a systematic review and meta-analysis. Int J Epidemiol. 2007;37(1):113-119.
29. Martinou AR, Timmis PM, Bothamley GH, et al. High-dose vitamin D3 during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomized controlled trial. Lancet. 2011;377(9771):242-250.
30. Weige C, Gomez CV, Rabara P, et al. Vitamin D as supplementary treatment for tuberculosis: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2009;179(9):843-850.
31. Dao CN, Patel P, O’Connor ET, et al. Low vitamin D among HIV-infected adults: prevalence and risk factors for low vitamin D levels in a cohort of HIV-infected adults and comparison to prevalence among adults in the US general population. Clin Infect Dis. 2011;52(3):394-405.
32. Haug CJ, Aukrust P, Haug E, et al. Severe deficiency of 1,25-dihydroxyvitamin D3 in human immunodeficiency virus infection: association with immunological hyperactivity and only minor changes in calcium homeostasis. J Clin Endocrinol Metab. 1998;83(11):3802-3808.
33. Pasquet A, Yiget N, Aljona F, et al. Vitamin D deficiency in HIV-infected patients: associated with non-nucleoside reverse transcriptase inhibitor or efavirenz use? AIDS. 2011;25(6):873-874.
34. Beard JA, Bearden A, Stiker R, Vitamin D and the anti-viral state. J Clin Virol. 2011;50(3):174-200.
35. Kühlmann AV, Trump DL, Johnson CS, Feldman D. The role of vitamin D in cancer prevention and treatment. Endocrinol Metab Clin North Am. 2010;39(2):401-418.
36. Bikle D. Nonclassic actions of vitamin D. J Clin Endocrinol Metab. 2009;94(1):26-34.
37. Trump DL, Deeb KK, Johnson CS. Vitamin D: considerations in the continued development as an agent for cancer prevention and therapy. Cancer J. 2010;16(1):1-9.
38. Rasini M, Mazzoni L, Mazzoni M. Vitamin D deficiency in rheumatoid arthritis: prevalence, determinants and associations with disease activity and disability. Arthritis Res Ther. 2010;12(2):R16.
39. Cutolo M, Pizzoni C, Squ A. Vitamin D endocrine system involvement in autoimmune rheumatic diseases. Autoimmun Rev. 2011;11(2):84-87.
40. Munger KL, Levin L, Hollis BW, et al. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA. 2006;296(23):2832-2838.
41. Moll G, Hanania NA. Vitamin D and asthma. Curr Opin Pulm Med. 2011;17(7):1-5.
42. McGrath JJ, Burne TH, Feron F, et al. Developmental vitamin D deficiency and risk of schizophrenia: a 10-year update. Schizophr Bull. 2010;36(6):1073-1078.
43. Pappas HM, Eren K, Kamin D, Grand RJ. Vitamin D status in gastrointestinal and liver disease. Curr Opin Gastroenterol. 2008;24(2):174-183.
44. Liewellyn DJ, Lang IA, Lambe KM, et al. Vitamin D and risk of cognitive decline in elderly persons. Arch Intern Med. 2010;170(13):1135-1141.
45. Holick MF, Blinken NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(7):2011-1930.